New stock news | Cofoe Medical Technology (01187) has received a subscription amount of HK$3.274 billion for its initial public offering, oversubscribed by 307.3 times. The entry fee for one lot is HK$3,972.7.

Cofoe Medical Technology (01187) will be open for subscription from April 27th to 30th, with plans to issue 27 million H shares. Ten percent will be offered in Hong Kong as public offering, with a maximum subscription price of 39.33 Hong Kong dollars and a maximum fundraising amount of 1.06 billion Hong Kong dollars. Each lot consists of 100 shares, with an entry fee of 3972.7 Hong Kong dollars. Cofoe Medical Technology is expected to be listed for trading on May 5th. Huatai International and FaBa serve as joint sponsors. As of noon on April 30th, Cofoe Medical Technology has received 32.74 billion Hong Kong dollars in subscription, which is 307.3 times oversubscribed based on the public offering amount of 1.06 billion Hong Kong dollars. The prospectus shows that Cofoe Medical Technology is one of China's largest home medical equipment companies. Since its establishment in 2007, the company has been deeply involved in the home medical equipment industry, always committed to providing convenient solutions for consumers and patients seeking high-quality and advanced home medical equipment. As of the latest practicable date, Cofoe Medical Technology's product portfolio covers over 200 product categories and tens of thousands of product specifications. With changes in modern society's demographics and lifestyles, the company strategically focuses on five categories of home medical equipment with strong growth potential and significant market demand, including rehabilitation aids, medical care products, health monitoring products, respiratory support products, and traditional Chinese medical therapy products, among others. Specifically, in 2024, based on domestic revenue, the company ranks first among all rehabilitation aid product companies in China, with a market share of 2.4%. By 2024, the Chinese home rehabilitation aid product market accounts for 23.5% of the Chinese home medical equipment market. Cofoe Medical Technology implements a multi-brand marketing strategy to meet the diverse needs of patients and customers. By giving each brand a unique market position and target customer group, while ensuring all brands share the core values of the company's main brand, the company has successfully established a comprehensive product portfolio with a large number of branded products. In 2025, the company also reached a strategic cooperation agreement with Royal Philips, through which the company obtained authorization to distribute Philips brand health monitoring products in the Greater China region. In the past performance period, the company had 11 proprietary brands and mainly sold products from 16 third-party brands. Cofoe Medical Technology has introduced 12 cornerstone investors, including Lens Technology (06613), Lens Technology (Hong Kong), Changsha Yufeng, Yuanxin Investment and China Galaxy International Investment (for Yuanxin Investment's OTC derivative), Panjing Fund, FR M CONSULTING, Hanqingda Industry, Dacheng International, Zhongkang Technology (02361), ODI TRUST, chairman of Shenglan Technology Huang Xuelin, Chairman of VIVO's affiliated Yunling Limited Dai Junan, and Lu Qinchao, with a total investment of 48.49 million dollars.